Oral Wegovy vs Foundayo
Two GLP-1 weight loss pills, both approved within four months of each other. Oral Wegovy is a daily semaglutide pill made by Novo Nordisk (approved December 2025). Foundayo is a daily orforglipron pill made by Eli Lilly (approved April 2026). Same goal, different drugs — here is how they compare in the data.
Quick read · 6 min
- •Oral Wegovy showed about 3 percentage points more weight loss than Foundayo in an indirect comparison of their clinical trials (ORION study)
- •Foundayo can be taken any time of day with no food or water restrictions — Oral Wegovy requires 30 minutes of fasting and a small sip of water
- •Both start at ~$149/month self-pay. Foundayo doses up to $349/month at the highest dose. Foundayo may be covered by Medicare Part D from July 2026 at ~$50/month
- •There is no head-to-head trial in obesity — the comparison data comes from matching patients across separate trials
The key difference in 30 seconds
Both are daily pills that reduce appetite through the GLP-1 pathway. The practical trade-off comes down to two things: weight loss and convenience.
For a 240 lb person, that means roughly 40 lbs lost with Oral Wegovy vs 30 lbs with Foundayo — a difference of about 10 lbs. Individual results vary substantially in both directions.
What the clinical data shows
No head-to-head trial exists yet
There is no randomised trial that directly compared these two drugs in people with obesity. What we have is an indirect comparison — researchers matched patient populations across two separate trials (OASIS-4 for oral Wegovy and ATTAIN-1 for Foundayo) and compared the results.
Indirect comparisons are useful but less reliable than head-to-head trials. Different trial designs, populations, and timeframes all add uncertainty.
ORION study (indirect comparison, presented at OMA 2026)
Researchers compared oral semaglutide 25mg (from OASIS-4) with orforglipron 36mg (from ATTAIN-1) using population-adjusted matching. The findings:
Side-by-side comparison
| Oral Wegovy | Foundayo | |
|---|---|---|
| Generic name | Semaglutide 25mg | Orforglipron 36mg |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA approved | December 2025 | April 2026 |
| Avg weight loss | ~16.6% (full adherence) ~13.6% intent-to-treat | ~12.4% highest dose, 72 weeks |
| How you take it | Daily pill, empty stomach, 30 min before food | Daily pill, any time, no restrictions |
| Cost (self-pay) | ~$149/month | $149–$349/month dose-dependent via LillyDirect |
| Heart benefit | Yes — SELECT trial (injection form) | Not yet studied |
| Common side effects | Nausea, diarrhea, constipation | Nausea, diarrhea, vomiting |
| Quit rate (side effects) | Lower in indirect comparison | ~4x higher odds of stopping (ORION indirect comparison) |
| Drug type | Peptide-based GLP-1 | Small molecule GLP-1 |
| Also available as | Weekly injection (Wegovy) | Pill only |
Convenience and daily life
This is the biggest practical difference between these two pills — and for some people, it matters more than the weight loss numbers.
Oral Wegovy
Take first thing in the morning on an empty stomach with no more than 4 ounces of plain water. Wait at least 30 minutes before eating, drinking anything else, or taking other medications. This timing is strict — the drug's absorption depends on it.
Foundayo
Take at any time of day. No fasting required. No restrictions on food, water, or other medications. This is currently the only oral GLP-1 with this flexibility. For people with variable schedules, shift work, or morning medication routines, this is a meaningful advantage.
Cost comparison
At the starting dose, both cost the same. At the highest dose (where the clinical trial results were measured), Foundayo costs more than double. Insurance coverage varies widely — check with your plan.
Trade-off summary
Oral Wegovy profile
- ✓Higher average weight loss in indirect comparison (~16.6% vs ~12.4%)
- ✓Proven cardiovascular benefit (SELECT trial data, injection form)
- ✓Lower discontinuation rate due to side effects
- ✓Flat ~$149/month at all doses
- ◆Strict 30-minute fasting requirement every morning
- ◆Cannot take with other morning medications
- ◆Absorption depends on following dosing instructions carefully
Foundayo profile
- ✓No food, water, or timing restrictions — take any time of day
- ✓Can take alongside other medications without timing conflicts
- ✓Medicare Part D coverage expected from July 2026 (~$50/month)
- ◆Lower average weight loss in indirect comparison (~12.4% vs ~16.6%)
- ◆Higher discontinuation rate due to side effects in ORION analysis
- ◆No cardiovascular benefit data yet
- ◆Higher cost at the maximum dose ($349/month vs $149/month)
- ◆Brand new — less real-world experience than semaglutide
What about injections?
If you are comparing pills specifically because you want to avoid injections, these are your two main GLP-1 options. But it is worth knowing that injectable versions generally show higher weight loss in trials:
These two pills differ in weight loss, convenience, cost at higher doses, and cardiovascular evidence. Neither is universally better — they represent a genuine trade-off between efficacy and flexibility. A doctor can help weigh these factors in the context of your specific situation.
Not sure where to start? Our 2-minute quiz can help.
Take the quiz →Based on clinical trials · No rankings · Every claim linked to source
Last reviewed: March 2026